Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pliant Therapeutics Discontinues IPF Program Due to Safety Concerns

Pliant Therapeutics has announced the termination of its idiopathic pulmonary fibrosis (IPF) program following an in-depth analysis of adverse events in a phase 2b/3 trial of its lead candidate, bexotegrast. The decision marks a significant setback for the California-based biotech company and highlights the challenges in developing treatments for this severe lung disease.

NoahAI News6/30/2025

Breakthrough in Ultrarare Disease Treatment: Customized Gene Therapy Paves the Way for Future Innovations

In a groundbreaking development, the pharmaceutical industry has witnessed the successful administration of a custom-made gene therapy for an ultrarare disease, marking a significant milestone in personalized medicine. This advancement, coupled with regulatory changes and technological progress, is reshaping the landscape of treatments for rare genetic conditions.

NoahAI News6/30/2025

FDA Approvals Drive Innovation in RSV, Cancer, and Hepatitis C Treatment

In a flurry of regulatory activity this June, the FDA has greenlit several groundbreaking therapies, expanding treatment options for respiratory syncytial virus (RSV), various cancers, and hepatitis C. These approvals underscore the pharmaceutical industry's ongoing commitment to addressing unmet medical needs and improving patient outcomes.

NoahAI News6/30/2025

FDA Declines Accelerated Approval for Edgewise's Muscular Dystrophy Drug

The U.S. Food and Drug Administration (FDA) has declined to consider Edgewise Therapeutics' investigational skeletal myosin blocker sevasemten for accelerated approval in the treatment of Becker muscular dystrophy (BMD). The decision, announced on June 27, 2025, has sent ripples through the pharmaceutical industry and raised questions about the future of muscular dystrophy treatments.

NoahAI News6/28/2025

Altimmune's Pemvidutide Shows Mixed Results in Phase IIb MASH Study

Altimmune, a clinical-stage biopharmaceutical company, faced a significant setback as its dual GLP-1/glucagon agonist pemvidutide delivered mixed results in a Phase IIb trial for metabolic dysfunction-associated steatohepatitis (MASH). The news sent shockwaves through the biotech sector, causing Altimmune's stock to plummet 53% following the data readout.

NoahAI News6/28/2025

Pharmaceutical Industry Roundup: BioCryst Divests European Business, FDA Vaccine Policy Criticized, and Clinical Trial Updates

BioCryst Pharmaceuticals has announced the sale of its European business for its hereditary angioedema drug Orladeyo to Italy's Neopharmed Gentili. The deal, valued at $250 million upfront with potential additional milestone payments of $14 million, includes the transfer of BioCryst's European sales organization to Neopharmed.

NoahAI News6/28/2025

Alto's Depression Drug Misses Primary Endpoint in Phase II Trial, Shows Promise in Exploratory Outcomes

Alto Neuroscience's investigational oral H3 receptor blocker, ALTO-203, failed to meet its primary endpoint in a Phase II trial for major depressive disorder (MDD). Despite this setback, the company reported encouraging results in exploratory outcomes, suggesting potential applications in other indications.

NoahAI News6/28/2025

Mazdutide Breaks New Ground in GLP-1 Obesity Drug Class with China Approval

Eli Lilly and Innovent Biologics have achieved a significant milestone in the development of incretin medicines for obesity treatment. China's National Medical Products Administration (NMPA) has granted approval for mazdutide, a novel dual GLP-1/glucagon (GCP) receptor agonist, marking it as the world's first in its class.

NoahAI News6/28/2025

CytoDyn Faces Investor Lawsuit Amid Ongoing Legal Troubles

In a significant development for the pharmaceutical industry, biotechnology company CytoDyn and its former executives are set to face a lawsuit from investors alleging misleading claims regarding the company's lead drug candidate, leronlimab. This legal challenge comes amidst a series of setbacks for the company, including regulatory hurdles and criminal convictions of former leadership.

NoahAI News6/28/2025

UCB's Fintepla Shows Promise in Third Epilepsy Indication

UCB's anti-epileptic drug Fintepla has demonstrated positive results in a phase 3 trial for CDKL5 deficiency disorder (CDD), potentially paving the way for its use in a third epilepsy indication. The Brussels-based pharmaceutical company announced on June 27 that the study achieved its primary endpoint and most secondary endpoints, marking a significant milestone in the treatment of this ultra-rare genetic condition.

NoahAI News6/28/2025

Stryker Announces Leadership Changes in Digital and Robotics Division

Stryker, a leading medical technology company, has made significant changes to its digital and robotics leadership team, reflecting the growing importance of these technologies in the medical device industry.Stryker has named Mike Carlin as the new President of digital, robotics and enabling technologies. Carlin, who previously served as the President of customer solutions at Stryker, will take over the leadership of this crucial segment as the company experiences substantial growth in robotic surgeries.

NoahAI News6/28/2025

Xoma Royalty Acquires Turnstone Biologics in $8M Deal, Marking End of Once-Promising Biotech

Turnstone Biologics, a once-promising biotech company that had secured partnerships with pharmaceutical giants AbbVie and Takeda, has reached its final chapter. In a surprising turn of events, Xoma Royalty has announced its acquisition of Turnstone for a mere $7.9 million, or $0.34 per share in cash. This low-profile exit comes as a stark contrast to Turnstone's previous success in attracting hundreds of millions of dollars from investors and partners.

NoahAI News6/28/2025

1 2 3 4...67 »